February 20, 2026
Greece has spent the last several years building a tightly controlled framework for the cultivation and manufacture of final pharmaceutical cannabis products. The commercial story now taking shape is export-led: industry and press coverage in 2024–2025 has repeatedly pointed to Athens’ interest in converting early investment into reliable outbound supply for major EU demand centers.
Two features make Greece unusually interesting for exporters:
At the same time, the hard part for would-be exporters is not “getting licensed” in the abstract—it is executing a credible EU-GMP operating model across cultivation inputs (GACP expectations), manufacturing controls (EudraLex Volume 4), quality documentation, and destination-market labeling and release requirements.
This article summarizes what is currently known (as of Feb 20, 2026) about Greece’s access rules and export authorization path, then translates the likely policy direction into a practical readiness list for GMP exporters targeting priority EU buyers.
Informational only, not legal advice.
Greece’s modern framework for medicinal production was enabled by Law 4523/2018 (Government Gazette A’ 41/07.03.2018), which opened the door to licensed cultivation, processing, storage, transport, and supply under strict conditions. The detailed operating requirements have been shaped through Joint Ministerial Decisions and regulator guidance.
A widely cited implementing measure is Joint Ministerial Decision No. oik. 51483/700/Φ.15 (referenced in multiple summaries as setting “terms and conditions for cultivation and processing”). Guidance packaged in English by Greek authorities and investment agencies has been used to brief investors on licensing and facility expectations.
For businesses evaluating the ecosystem, two official starting points are:
Greece’s patient access has been slow to operationalize compared to some EU peers. Media reporting in early 2024 indicated the first legal prescriptions and product availability in pharmacies occurred in February 2024, after a long lead-in period.
Examples of coverage include:
From a compliance perspective, what matters is that Greek authorities treat these products as pharmaceutical preparations subject to controlled distribution and regulatory documentation. EOF has published a dedicated section that includes references to:
See EOF’s medicinal cannabis page (English): https://www.eof.gr/en/farmaka-farmakeftiki-kanavi/
A major policy feature affecting both domestic competition and local investment has been Greece’s restriction on importing finished medical products for domestic consumption. The issue reached EU-level political attention; for example, a European Parliament question notes that on 2 December 2021 the Greek government banned imports of finished medical products for domestic use.
Source:
For exporters, this matters indirectly: it signals a policy preference for in-country production—which can support investment cases—while also keeping domestic commercial volumes relatively limited compared with export opportunity.
Exporting from Greece is not a single permission. It is a stack:
EOF’s medicinal cannabis page includes specific references to:
Official landing page: https://www.eof.gr/en/farmaka-farmakeftiki-kanavi/
Practical takeaway: if your strategy is export-only, EOF already signals an approval lane focused on production capacity exclusively for export. If you intend to serve Greece domestically, you should expect additional EOF scrutiny around circulation approval, product information, and prescribing/dispensing controls.
Even where a destination market allows non-GMP pathways in limited circumstances, the dominant EU procurement and pharmacy channels typically expect EU-GMP certification and robust quality systems aligned to EudraLex Volume 4.
Authoritative reference:
For Greek exporters, the key operational implication is that “GMP readiness” is not just facility design; it includes:
Many EU markets treat these products as medicinal products, magistral preparations, or controlled substances under national rules. Acceptance is driven by the importing country’s legal classification, permitted dosage forms, and import licensing.
Some Greek-facing policy commentary has emphasized that export products may be assessed primarily against the importing country’s requirements. That approach may reduce duplicative constraints at home, but it increases your burden to build country-by-country dossiers.
In 2025, multiple reputable outlets reported that Greece was preparing or considering a draft bill intended to boost investment and exports in this sector.
Notable coverage includes:
Because legislative text and implementing circulars are what ultimately matter, compliance teams should treat press summaries as directional signals and track:
Based on the policy intent described in 2025 reporting and common EU export friction points, the most plausible “acceleration” areas are:
Important nuance: even if Greece streamlines its side, exporters still face the importing country’s requirements (permits, narcotics office approvals, pharmacy channel rules, and language/leaflet formatting).
At a high level, Greece operates a prescription-based medical model for qualified patients through controlled channels. Public reporting indicates that prescriptions and access became practical in February 2024, and EOF’s framework centers around “final pharmaceutical” products.
Consumer-facing compliance risks businesses should plan for include:
The biggest compliance burdens are upstream:
Even without a retail-style seed-to-sale system, exporters should assume they will be asked to demonstrate end-to-end traceability consistent with pharmaceutical norms.
Below is a workflow exporters can use to structure their planning. The exact sequence and responsible authorities can vary by business model and destination market, but this reflects how successful EU exporters generally operate.
Start here:
Inspection outcomes depend on what inspectors see in operation:
Anchor your program to:
Before you finalize your SKU strategy, determine how each target country will treat the product:
This classification drives:
Export buyers and regulators will expect stability data supporting:
Stability is often the gating item that delays first shipments—especially if you are changing packaging to meet a destination language or child-resistant requirement.
Even when the active “product information” is harmonized, the physical pack and leaflet must meet national language and formatting rules.
Helpful EU-wide references:
Operational takeaway: treat labeling as a validated process with version control, reconciliation, and a robust line clearance program.
Export shipments require more than a commercial invoice:
Even in export-only models, authorities and sophisticated buyers will evaluate your GDP-like controls for storage and transport.
Below is a practical checklist aligned to the “export boost” narrative. Use it to run internal audits, vendor selection, and pre-inspection planning.
Prioritize these areas because they most frequently trigger major findings:
Even if cultivation itself is not “GMP,” the export customer will still care about:
Document the bridge: how agricultural controls translate into GMP-compliant starting materials.
Build your export launch plan around stability reality:
Deliverable to prepare: a stability summary and protocol set that a buyer’s QA team can review.
For each target EU market, define:
Deliverable to prepare: controlled artwork files, translation certificates/workflows, and packaging line clearance SOPs.
Even if the Greek manufacturer produces and tests product, the importing country may require:
Deliverable to prepare: a standardized batch release dossier (CoA, manufacturing narrative, deviations summary, stability commitment, transport conditions).
Before the first shipment, execute:
This is where many first-time exporters lose time: buyers will not onboard without it.
When policy shifts encourage faster investment and exports, enforcement typically follows the risk areas regulators know will break under speed:
The “export boost” opportunity is real, but the penalty for getting it wrong is also real: shipment holds, rejected batches, buyer delisting, and potentially license risk.
If you’re preparing for Greece medical cannabis exports 2025 and beyond—whether as a licensed producer, a contract manufacturer, or an EU buyer onboarding Greek supply—turn readiness into a managed program: gap assessment, document control, labeling governance, and inspection preparation.
Use https://cannabisregulations.ai/ to organize requirements by jurisdiction, track licensing and compliance changes, and build an audit-ready export playbook.
